Advertisement
Advertisement
ASND
Ascendis Pharma A/S Ordinary Share
247.51
USDSponsored
+6.17
+2.56%
May 21, 16:00 UTC -4
Closed
After-Market
247.31
-0.19
-0.08%
ASND Earnings Reports
Positive Surprise Ratio
ASND beat 16 of 42 last estimates.
38%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$345.35M
/$1.09
Implied change from Q1 26 (Revenue/ EPS)
+40.04%
/-241.56%
Implied change from Q2 25 (Revenue/ EPS)
+118.51%
/-270.31%
Ascendis Pharma A/S Ordinary Share earnings per share and revenue
On May 07, 2026, ASND reported earnings of -0.77 USD per share (EPS) for Q1 26, missing the estimate of 0.20 USD, resulting in a -471.08% surprise. Revenue reached 246.60 million, compared to an expected 275.57 million, with a -10.51% difference. The market reacted with a +4.13% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of 1.09 USD, with revenue projected to reach 345.35 million USD, implying an decrease of -241.56% EPS, and increase of 40.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Ascendis Pharma A/S Ordinary Share's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ascendis Pharma A/S Ordinary Share reported EPS of -$0.77, missing estimates by -471.08%, and revenue of $246.60M, -10.51% below expectations.
How did the market react to Ascendis Pharma A/S Ordinary Share's Q1 2026 earnings?
The stock price moved up 4.13%, changed from $220.28 before the earnings release to $229.38 the day after.
When is Ascendis Pharma A/S Ordinary Share expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Ascendis Pharma A/S Ordinary Share's next earnings report?
Based on 12
analysts, Ascendis Pharma A/S Ordinary Share is expected to report EPS of $1.09 and revenue of $345.35M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement